시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 클라우딘 18.2 표적치료 시장 보고서(2025년)
Claudin 18.2 Targeted Therapy Global Market Report 2025
상품코드 : 1855826
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,684,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,662,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,639,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

클라우딘 18.2 표적치료 시장 규모는 최근 급격히 확대되고 있습니다. 2024년 12억 9,000만 달러에서 2025년에는 16억 달러에 달하고, CAGR 23.9%로 성장할 전망입니다. 연구개발 활동의 활성화, 정부 및 기관 지원의 확대, 췌장암 이환율의 상승, 암 의료에의 헬스케어 투자 증가, 표적치료에의 세계적인 액세스의 확대 등이 성장을 견인할 전망입니다.

클라우딘 18.2 표적치료 시장 규모는 향후 수년간 비약적인 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 23.6%로 37억 3,000만 달러로 성장할 전망입니다. 예측 기간 동안 성장의 원동력은 클라우딘 18.2 표적치료제의 승인 증가, 위암 및 위 식도 접합부 암의 유병률 증가, 클라우딘 18.2 지향성 치료제의 파이프라인 확대, 제약 기업의 관심 증가, 맞춤 의료 채택 증가입니다. 예측기간에 있어서의 1차 동향으로는 단일클론항체 개발의 기술 진보, 이특이성 항체 요법의 혁신, 항체 약물 복합체의 진보, 바이오마커의 발견과 검증에 대한 투자, 병용 요법의 연구 개발 등을 들 수 있습니다.

소화기 암의 발생률 증가가 클라우딘 18.2 표적치료 시장의 확대를 촉진할 것으로 예측됩니다. 소화관(GI) 암은 식도에서 직장까지 소화관의 어느 곳에서나 발생할 수 있는 악성 종양입니다. GI암 증가는 가공식품이 많고 식이섬유가 적은 건강에 해로운 식생활에 기인하는 것이 크며, 이들은 장 내의 염증을 촉진하고 암의 리스크를 높입니다. 클라우딘 18.2 표적치료는 암세포에서 과발현하고 있는 클라우딘 18.2 단백질에 대해 표적 특이적으로 작용합니다. 이에 따라 약제와 항체는 건강한 조직을 손상시키지 않고 암세포를 선택적으로 죽일 수 있어 치료효과가 향상됩니다. 국립의학도서관의 2025년 7월 보고서에 따르면 2022년에는 소화기암의 신규 환자수는 478만 3,391명, 사망자수는 323만 5,719명으로 세계 신규암 환자 수의 23.9%, 암 관련 사망자 수의 33.2%를 차지했습니다. 따라서, 소화기 암 증례의 증가가 클라우딘 18.2 표적치료 시장의 성장을 견인하고 있습니다.

클라우딘 18.2 표적치료 시장의 주요 기업은 클라우딘 18.2를 발현하는 암세포를 표적으로 하는 단일클론항체 등의 선진적 솔루션의 개발에 주력하여 치료 결과를 향상시키고 있습니다. 단일클론항체는 암세포의 표면에 존재하는 단백질 등의 특정 표적에 결합하도록 설계된 실험실 설계 단백질이며, 면역계가 이들 세포를 인식하고 공격하도록 돕습니다. 2024년 3월 일본 제약회사인 아스텔라스 제약은 CLDN18.2 양성 암 환자를 대상으로 한 치료제인 VYLOY(졸베툭시맙)의 승인을 후생노동성으로부터 취득했습니다. 진행 중인 위암 및 위식도 접합부 암에 대한 이 분자 표적치료제는 암세포 상의 CLDN18.2 단백질과 선택적으로 결합하여 면역계를 활성화하여 암세포를 파괴합니다. 임상시험은 화학요법과 병용한 경우 화학요법 단독에 비해 무증상 생존기간 및 전체 생존기간이 유의하게 개선되는 것으로 나타났습니다. 이 새로운 치료는 HER2 음성 CLDN18.2 양성 종양을 가진 환자에게 효과적인 새로운 치료 옵션을 제공하고 침공성 위암에서 중요한 미충족 요구에 대응합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Claudin 18.2 targeted therapy is an advanced precision cancer treatment designed to selectively target the Claudin 18.2 protein, which is abnormally overexpressed on the surface of certain tumor cells. This therapy specifically attacks cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues.

The primary therapy types of Claudin 18.2 targeted therapy are monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are laboratory-engineered molecules that bind to specific proteins on cancer cells, enabling the immune system to target and destroy them. These therapies are primarily indicated for gastric cancer, pancreatic cancer, esophageal cancer, and others, and are administered via intravenous, oral, and other routes. Key end users include hospitals, oncology centers, research institutes, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The claudin 18.2 targeted therapy market research report is one of a series of new reports from The Business Research Company that provides claudin 18.2 targeted therapy market statistics, including claudin 18.2 targeted therapy industry global market size, regional shares, competitors with a claudin 18.2 targeted therapy market share, detailed claudin 18.2 targeted therapy market segments, market trends and opportunities, and any further data you may need to thrive in the claudin 18.2 targeted therapy industry. This claudin 18.2 targeted therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The claudin 18.2 targeted therapy market size has grown exponentially in recent years. It will grow from $1.29 billion in 2024 to $1.60 billion in 2025 at a compound annual growth rate (CAGR) of 23.9%. The growth during the historic period was driven by increasing research and development activities, growing government and institutional support, rising incidence of pancreatic cancer, higher healthcare investments in oncology, and expanding global access to targeted therapies.

The claudin 18.2 targeted therapy market size is expected to see exponential growth in the next few years. It will grow to $3.73 billion in 2029 at a compound annual growth rate (CAGR) of 23.6%. The growth during the forecast period is fueled by rising approvals of Claudin 18.2 targeted therapies, increasing prevalence of gastric and gastroesophageal junction cancers, an expanding pipeline of Claudin 18.2 directed therapies, growing interest from pharmaceutical companies, and rising adoption of personalized medicine. The primary trends in the forecast period include technological advancements in monoclonal antibody development, innovations in bispecific antibody therapies, progress in antibody-drug conjugates, investment in biomarker discovery and validation, and research and development in combination therapies.

The growing incidence of gastrointestinal cancers is expected to drive the expansion of the claudin 18.2 targeted therapy market. Gastrointestinal (GI) cancers are malignant tumors that can develop anywhere in the digestive tract, from the esophagus to the rectum. The increase in GI cancers is largely attributed to unhealthy diets that are high in processed foods and low in fiber, which promote inflammation in the gut and elevate the risk of cancer. Claudin 18.2 targeted therapy works by specifically targeting the Claudin 18.2 protein, which is overexpressed in cancer cells. This allows drugs or antibodies to selectively kill cancer cells while leaving healthy tissue unharmed, improving the effectiveness of treatment. According to a July 2025 report from the National Library of Medicine, in 2022, GI cancers accounted for 4,783,391 new cases and 3,235,719 deaths, representing 23.9% of all new cancer cases and 33.2% of cancer-related deaths worldwide. As a result, the rising number of gastrointestinal cancer cases is driving the growth of the claudin 18.2 targeted therapy market.

Leading companies in the claudin 18.2 targeted therapy market are focusing on developing advanced solutions, such as monoclonal antibodies, that target claudin 18.2-expressing cancer cells to improve treatment outcomes. Monoclonal antibodies are lab-engineered proteins designed to bind to specific targets, such as proteins found on the surface of cancer cells, helping the immune system recognize and attack these cells. In March 2024, Astellas Pharma Inc., a pharmaceutical company based in Japan, received approval from Japan's Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab), a treatment for patients with CLDN18.2-positive cancer. This targeted therapy for advanced gastric and gastroesophageal junction cancer selectively binds to the CLDN18.2 protein on cancer cells, activating the immune system to destroy them. Clinical trials demonstrated that when combined with chemotherapy, it significantly improves progression-free and overall survival compared to chemotherapy alone. This novel therapy provides an effective new treatment option for patients with HER2-negative, CLDN18.2-positive tumors, addressing a significant unmet need in aggressive gastric cancer.

In February 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. With this acquisition, AstraZeneca aims to advance its cell therapy strategy by enhancing its pipeline with Gracell's innovative CAR-T therapies, which target blood cancers and autoimmune diseases. AstraZeneca plans to leverage Gracell's FasTCAR platform to improve treatment effectiveness and manufacturing efficiency. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company based in China, also offers claudin 18.2 targeted therapy.

Major players in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.

Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2024. The regions covered in claudin 18.2 targeted therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the claudin 18.2 targeted therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The claudin 18.2 targeted therapy market consists of sales of zolbetuximab, CMG901, and bispecific antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Claudin 18.2 Targeted Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on claudin 18.2 targeted therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for claudin 18.2 targeted therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The claudin 18.2 targeted therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Claudin 18.2 Targeted Therapy Market Characteristics

3. Claudin 18.2 Targeted Therapy Market Trends And Strategies

4. Claudin 18.2 Targeted Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Claudin 18.2 Targeted Therapy Growth Analysis And Strategic Analysis Framework

6. Claudin 18.2 Targeted Therapy Market Segmentation

7. Claudin 18.2 Targeted Therapy Market Regional And Country Analysis

8. Asia-Pacific Claudin 18.2 Targeted Therapy Market

9. China Claudin 18.2 Targeted Therapy Market

10. India Claudin 18.2 Targeted Therapy Market

11. Japan Claudin 18.2 Targeted Therapy Market

12. Australia Claudin 18.2 Targeted Therapy Market

13. Indonesia Claudin 18.2 Targeted Therapy Market

14. South Korea Claudin 18.2 Targeted Therapy Market

15. Western Europe Claudin 18.2 Targeted Therapy Market

16. UK Claudin 18.2 Targeted Therapy Market

17. Germany Claudin 18.2 Targeted Therapy Market

18. France Claudin 18.2 Targeted Therapy Market

19. Italy Claudin 18.2 Targeted Therapy Market

20. Spain Claudin 18.2 Targeted Therapy Market

21. Eastern Europe Claudin 18.2 Targeted Therapy Market

22. Russia Claudin 18.2 Targeted Therapy Market

23. North America Claudin 18.2 Targeted Therapy Market

24. USA Claudin 18.2 Targeted Therapy Market

25. Canada Claudin 18.2 Targeted Therapy Market

26. South America Claudin 18.2 Targeted Therapy Market

27. Brazil Claudin 18.2 Targeted Therapy Market

28. Middle East Claudin 18.2 Targeted Therapy Market

29. Africa Claudin 18.2 Targeted Therapy Market

30. Claudin 18.2 Targeted Therapy Market Competitive Landscape And Company Profiles

31. Claudin 18.2 Targeted Therapy Market Other Major And Innovative Companies

32. Global Claudin 18.2 Targeted Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Claudin 18.2 Targeted Therapy Market

34. Recent Developments In The Claudin 18.2 Targeted Therapy Market

35. Claudin 18.2 Targeted Therapy Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기